IPO Review - Supriya Lifescience Ltd - ICICI Direct

Supriya Lifescience (SLL) is a manufacturer and supplier of active pharmaceuticals ingredients (APIs), with a focus on research and development.

• As of October 31, 2021, the company has niche product offerings of 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic
• Supriya has been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-50% and 60-65%, respectively, of the API exports from India, between FY17 and FY21. SLL is among the largest exporters of Salbutamol Sulphate in India contributing to 31% of the API exports from India in FY21 in volume terms

Key triggers / Highlights

• Expansion of manufacturing capabilities
• Expanding product portfolio with increasing R&D capabilities
• Increase in current market presence and entry into new markets
• Operational excellence in terms of cost and production efficiency

For details, click on the link below: Link to the report

Source : Equity Bulls

Keywords

IPOReview SupriyaLifescience ICICIDirect